ClinicaliQ Trial Snapshot
- Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases — Recruiting • Phase II • Cardiology / Cardiovascular • NCT05003986.
- What is being tested: Sparsentan (a dual endothelin receptor antagonist and angiotensin II receptor blocker) administered as oral suspension or tablets in once-daily dosing regimens, with primary focus on safety, tolerability, and proteinuria reduction over 108 weeks in the pediatric population.
- Patient eligibility overview: Children with proteinuric glomerular diseases (including conditions such as IgA nephropathy and focal segmental glomerulosclerosis) who meet specific inclusion criteria for age, proteinuria levels, and baseline renal function.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
Eligibility Snapshot
- for All Subjects (All Three Populations): A subject must meet all of the following criteria to be eligible for participation in this study: * The subject or parent/legal guardian (as appropriate) is willing and able to provide signed informed consent/assent, and where required, the subject is willing to provide assent before any screening procedures per local requirements. * The subject has an estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 at screening. * The subject has a mean seated blood pressure between the 5th and 95th percentile for sex and height. Inclusion Criteria for Population 1: * The subject is male or female ≥1 year at screening and
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.